Constitutive NF-κB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 725-732

  Xie, Tong Xin ^a   Xia, Zhibo ^b   Zhang, Nu ^a,b   Gong, Weida ^a   Huang, Suyun ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Glioblastoma; IL 8; NF B; Tumor angiogenesis; VEGF

Indexed keywords

I KAPPA B ALPHA; I KAPPA B ALPHA M; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MUTANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; MESSENGER RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; DOWN REGULATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77349094234     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000690     Document Type: Article

References (41)

1. Kleihues P, Louis DN, Scheithauer BW, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002.
2. American Cancer Society: Cancer Facts and Figures. 2008. Available at: http://www.cancer.org.
3. Surawicz TS, Davis F, Freels S, Laws ER Jr and Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40: 151-160, 1998.
4. Folkman J: Angiogenesis in cancer, vascular, rheuma rheumatoid and other disease. Nat Med 1: 27-31, 1995.
5. Kleihues P, Burger PC and Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3: 255-68, 1993.
6. Wong ML, Prawira A, Kaye AH and Hovens CM: Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 16: 1119-1130, 2009.
7. Machein M and de Miguel LS: Angiogenesis in gliomas. Recent Results Cancer Res 171: 193-215, 2009.
8. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG and Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622, 2007.
9. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992.
10. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis (mini review). Cell 79: 185-188, 1994.
11. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
12. Leung DW, Cachianes G, Kuang WH, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
13. Mukaida N, Okamoto S, Ishikawa Y and Matsushima K: Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 56: 554-581, 1994.
14. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG and Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801, 1992.
15. Heintz APM: Surgery in advanced ovarian carcinoma: is there proof to show the benefit? Eur J Oncol 14: 91-99, 1988.
16. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, Boviatsis EI, Barbatis C, Lea RW, Kalofoutis A and Korkolopoulou P: Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 70: 391-397, 2009.
17. Koong AC, Chen EY, Mivechi NF, Denko NC, Stambrook P and Giaccia AJ: Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res 54: 5273-5279, 1994.
18. Royds JA, Dower SK, Qwarnstrom EE and Lewis CE: Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 51: 55-61, 1998
19. Koong AC, Chen EY and Giaccia AJ: Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 54: 1425-1430, 1994.
20. Madrid LV, Mayo MW, Reuther JY and Baldwin AS Jr: Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276: 18934-18940, 2001.
21. Romashkova JA and Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90, 1999.
22. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999.
23. Mayo MW, Madrid LV, Westerheide SD, et al: PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 277: 11116-11125, 2002.
24. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S and Kumanishi T: Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96: 909-917, 2002.
25. Wang H, Wang H, Zhang W, Huang HJ, Liao WS and Fuller GN: Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951, 2004.
26. Huang S, DeGuzman A, Bucana CD and Fidler IJ: Nuclear factor-kB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 6: 2573-2581, 2000.
27. Huang S, Robinson JB, DeGuzman A, Bucana CD and Fidler IJ: Blockade of NF-κB signalling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Cancer Res 60: 5334-5339, 2000.
28. Huang S, Pettaway C, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001.
29. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary K R and Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999.
30. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, Black PM and Bours V: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10: 5595-5603, 2004.
31. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R and Lang FF: An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 92: 326-333, 2000.
32. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
33. Baldwin AS Jr: The NF-κB and IκB proteins: New discoveries and insights (review). Annu Rev Immunol 14: 649-683, 1996.
34. Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin AS Jr: A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Gene Dev 12: 968-981, 1998.
35. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U and Waes CV: Expression of a dominant-negative mutant inhibitor-κBα of NF-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res 59: 3468-3474, 1999.
36. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP and Bours V: Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 59: 811-815, 1999.
37. Pajonk F, Pajonk K and McBride WH: Inhibition of NF-κB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91: 1956-1960, 1999.
38. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA and Narayanan R: Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90: 9901-9905, 1993.
39. Wang W, Abbruzzese JL, Evans DB and Chiao PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated relA. Oncogene, 18: 4554-4563, 1999.
40. Yoshida A, Yoshida S, Khalil AK, Ishibashi T and Inomata H: Role of NF-κB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39: 1097-1106, 1998.
41. Shono T, Ono M, Izumi H, Jimi SI, Matsushima K, Okamoto T, Kohro K and Kuwano M: Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16: 4231-4239, 1996.